Illumina (ILMN) CEO Jay Flatley tells Bloomberg that while the fiscal cliff will affect a third of the gene-sequencing company's customers, "it's going to probably be pretty short-lived." Flatley also says that Roche going public in January with its $6.7B offer for Illumina stopped the board from properly discussing the offer and possibly put paid to the deal.
Illumina (ILMN) CEO Jay Flatley tells Bloomberg that while the fiscal cliff will affect a third...
From other sites
Video at CNBC.com (Jun 28, 2016)
Video at CNBC.com (Apr 19, 2016)
Video at CNBC.com (Oct 6, 2015)
at CNBC.com (Jan 9, 2015)
at CNBC.com (Dec 29, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs